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Abstract: Telomeres are DNA-tandem repeats situated at the ends of chromosomes and are responsible
for genome stabilization. They are eroded by increased cell division, age and oxidative stress with
shortened leucocyte telomeres (LTL) being associated with inflammatory disorders, including Type
II diabetes. We assessed LTL in 205 participants across glucose tolerance groups at baseline and
after three years in the mixed ancestry population of South Africa which have been shown to have
high rates of obesity and T2DM. Baseline and follow-up data included glucose tolerance status,
anthropometric measurements, lipids, insulin, γ-glutamyl transferase (GGT), cotinine, and HbA1c.
Telomere length was measured using the absolute telomere q-PCR method performed on a Bio-Rad
MiniOpticon Detector. No significant difference was detected in LTL across glucose tolerance groups
at both time points, including in subjects who showed a deterioration of their glucose tolerance
status. There was, however, a significant negative correlation between LTL and age which was more
pronounced in diabetes (r = −0.18, p = 0.04) and with GGT (r = −0.16, p = 0.027). This longitudinal
study has demonstrated that LTL shortening is not evident within three years, nor is it associated with
glycaemia. Further studies in a larger sample and over a longer time period is required to confirm
these results.
Keywords: leucocyte telomere length; hyperglycemia; type II diabetes
1. Introduction
Telomeres are DNA-proteins situated at the ends of linear chromosomes and consist of non-coding,
double-stranded, G-rich tandem repeats ranging in length from a few hundred base pairs in yeast to
several kilo-base pairs in vertebrates [1]. The double stranded telomeric DNA is not all packaged into
nucleosomes, and together with a single-stranded DNA overhang provides binding sites for a number
of proteins [2]. In addition, it serves as a substrate for the enzyme telomerase which elongates and
maintains telomere length [3]. The telomeric proteins play an important role in regulating telomere
maintenance and any change in expression could result in accelerated shortening or dysfunction [4].
This multi-protein-DNA complex therefore forms a cap at the ends of chromosomes and is responsible
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for genome stabilization which is achieved by providing protection from degradation. It is thought that
as cells replicate, telomeric DNA is sacrificed in order to preserve the coding regions of the genome [3,5].
This process continues until eventually a critical threshold is reached which results in cell senescence
and/or apoptosis [1].
Telomere length and structure are regulated by complex mechanisms involving interactions
between telomerase, the expression of associated proteins, such as TRF1 and TRF2 and telomere
architecture [3,4]. It has, however, been observed that telomerase activity decreases with age and that
telomere length is reduced in chronic inflammatory states. The mechanisms promoting this include
increased levels of reactive oxygen species (ROS), decreased nitric oxide and decreased Telomerase
reverse transcriptase (TERT) activity, all of which have been associated with the process of aging and
atherogenesis [6]. Apart from the increased inflammatory activity and cell division, telomere erosion
could also be caused by the release of ROS which causes damage to telomeric DNA by oxidative
stress [7]. Both obesity and type 2 diabetes mellitus (T2DM) have been recognized as states of increased
oxidative stress and it is understood that this could play a key role in progressive telomere shortening
in these individuals [8].
T2DM is a metabolic disorder characterized by chronic inflammation, insulin resistance and
increased risk of cardiovascular disease. It is the most common form of diabetes and accounts for
90–95% of all diabetes cases [9,10]. It is well recognized that obesity contributes to both the onset
of hyperglycemia and the characteristic chronic pro-inflammatory environment. T-Lymphocytes
and macrophages promote inflammation in adipose tissue by secreting pro-inflammatory cytokines,
adipokines and chemokines, all of which have a direct effect on glucose intolerance and insulin
resistance. The intensified inflammatory response promotes increased oxidative stress, elevated
advanced glycation end-product (AGE) production and macrophage stimulation [11,12].
Numerous reports have observed significantly shorter leucocyte telomeres in patients with
inflammatory diseases, however, evidence in T2DM remains scarce and controversial [9,13].
The mixed ancestry population of Cape Town is a heterogeneous South African ethnic group
comprising 32–43% Khoisan, 20–36% Bantu-speaking African, 21–28% European and 9–11% Asian
ancestry [14]. According to the 2011 population census of South Africa, this well described ethnic
group [15] makes up 48% of the Western Cape population and 76% of the inhabitants of the Bellville
South Community. [16]
Herein, we assessed leucocyte telomere length (LTL) in participants across all glucose tolerance
groups at baseline and after three years in the mixed ancestry population of South Africa that have
been shown to have high rates of obesity and T2DM [15].
2. Materials and Methods
2.1. Ethics
This investigation formed part of the Bellville South study which has been previously described [15].
Both the baseline and the three-year follow-up studies were approved by the Cape Peninsula University
of Technology, Faculty of Health and Wellness Sciences Ethics Committee (Reference Number:
CPUT/HW-REC 2008/002 and CPUT/HW-REC 2010 respectively). This sub-study was granted further
ethical approval (CPUT/HW-REC 2017/H2) and was carried out according to the Code of Ethics of the
World Medical Association (Declaration of Helsinki 2013).
2.2. Study Design and Clinical Procedures
The study was longitudinal and involved participants of the well described Bellville South
study [15,17]. Briefly, between 2008 and 2009 a cohort of mixed ancestry participants was recruited from
the Bellville South region and three-year follow-up evaluation of the same participants commenced in
February 2011 [17]. Participants were excluded if they were younger than 18 years, showed any clinical
signs of infection, were pregnant or were using immunosuppressant drugs. Furthermore, participants
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were only included if they had fasted overnight and had not taken aspirin or anti-inflammatory drugs
for a minimum of 14 days prior to sampling. Each individual filled in a standardized questionnaire
which included questions regarding previous medical history, diet, as well as lifestyle habits, such as
smoking and alcohol consumption.
All anthropometric measurements were performed according to World Health Organisation
guidelines and performed in triplicate with the average used for the final analysis. Blood pressure
measurements were taken using a semi-automated digital blood pressure monitor (Rossmax, Rossmax,
San Diego, CA, USA) and weight was measured in kilograms (kg) using a calibrated Sunbeam EB710
digital bathroom scale (Sunbeam, Cape Town, South Africa) while participants were wearing light
clothing and no shoes. Measurement of height was rounded off to the nearest centimeter (cm) and
performed using a portable stadiometer. The body mass index (BMI) was then calculated by dividing
the weight and height squared, BMI = Body mass (Kg)
height (m)2
.
A non-elastic tape was used to measure the waist circumference (WC) while subjects were standing
in an erect position. Measurements were taken with the investigator in front of the participant, and by
placing the measuring tape around the narrowest part of the torso as seen from the anterior view.
2.3. Blood Collection and Biochemical Assays
Following an overnight fast, blood samples were taken. In those participants with no history of
diagnosed diabetes, a further sample was taken after an oral glucose tolerance test (OGTT). Samples
for routine biochemical testing were sent to the Metropolis Private Pathology Laboratory, Cape Town
which is an ISO 15,189 accredited medical laboratory. Blood glucose (mmol/L) was measured using the
enzymatic hexokinase method while glycated hemoglobin (HbA1c) was determined by turbimetric
inhibition assay (Cobas 6000, Roche Diagnostics; Mannheim, Germany). Insulin (mmol/L) was tested
using a microparticle enzyme immunoassay (Axsym, Abbott, Abbott laboratories, Lake Bluff, IL, USA)
and Ultra-sensitive (U-CRP) was analyzed by Latex Particle Immunoturbidimetric methods (Beckman
AU (Beckman Coulter, Miami, FL, USA). Total cholesterol (TC), high density lipoprotein cholesterol
(HDL-c), triglycerides (TG) and the liver enzyme γ-Glutamyltransferase (GGT) were analyzed using
an enzymatic colorimetric method (Cobas 6000, Roche Diagnostics) while low density lipoprotein
(LDL was calculated using Friedewald’s formula. The liver enzymes, alanine aminotransferase (AST)
and aspartate transaminase (ALT) were measured using International Federation of Clinical Chemistry
and Laboratory Medicine (IFCC) standardized reagents on a Beckman AU (Beckman Coulter, Miami,
FL, USA) while serum cotinine was measured by Competitive Chemiluminescent on Immulite 2000
(Siemens, Berlin, Germany). Creatinine levels were determined on the Cobus 6000, Roche Diagnostics.
2.4. Glycaemic Status Classification
Classification of participants was done in accordance with the revised WHO criteria of 1999 [18].
History, fasting glucose, and 2-hour glucose following OGTT were used to classify participants as
normotolerant, prediabetes (impaired fasting glycaemia, impaired glucose tolerance or combination of
both), new diabetes, and known diabetes.
2.5. DNA Extraction and Freeze Thawing Procedures
DNA was extracted using the salt extraction method (www.genomics.liv.ac.uk, 2001) from
1–2 mL of whole blood collected in EDTA. After extraction, the DNA was stored at −80 ◦C in
a temperature-controlled freezer until analysis took place. On the day of analysis samples were taken
out of storage and kept at 4 ◦C. The concentration and quality of the freeze-thawed DNA were both
assessed using a nanodrop (Nanodrop Technologies, Wilmington, NC, USA) and samples included for
analysis all had an OD (optical density) ratio A260/A280 > 1.8.
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2.6. Telomere Length Measurement
The method used to measure leucocyte telomere length was adopted from a protocol devised
by O’Callaghan and Fenech [19]. Standards and primers used for the assay were obtained from
Sigma-Aldrich/Merck (Saint Louie, MO, USA) and after purification and the removal of long oligomers
(>50 mers), the oligomer standards and primers were diluted in Tris-EDTA to obtain a concentration of
100 µM. Thereafter they were vortexed, centrifuged for one minute and stored at −20 ◦C until required.
To control for the plate effect, Standards and controls were placed on the first and the middle column
and triplicates of samples were not place consecutively.
2.7. The Standard Curve for Human Single Copy Gene (SCG), 36B4
PCR-grade water was used to dilute the telomere standard (84 mer oligonucleotide TTAGGG
repeats). This was used to create a standard curve in order to calculate the number of repeats in each
standard. A single copy gene (SCG) was included as a control and was used to determine the number
of genome copies per sample. The 36B4 SCG is the most commonly used control, encodes the acidic
ribosomal phosphoprotein (P0) and was used for all samples.
2.8. Calculation of the Genome Copy Number
The synthesized 36B4 oligomer standard was 75bp in length with a molecular weight (MW)
of 23,268.1. The weight of one molecule was MW/Avogadro’s number and therefore the weight of
the standard was: 2.32681 × 104/6.02 × 1023 = 0.38 × 10−19 g. The highest concentration standard,
(36B4 SCG STD), had 200 pg of 36B4 oligomer (200 × 10−12 g) per reaction and hence contained:
200 × 10−12/0.38 × 10−19 = 5.26 × 109 copies of 36B4 amplicon. The 36B4 SCG standard was equivalent
to 2.63 × 109 diploid genome copies, as there are two copies of 36B4 per diploid genome. A standard
curve was produced by performing serial dilutions of the 36B4 SCG STD (10−1 to 10−6 dilution).
Plasmid DNA (pBR322) was added to each standard to maintain a constant 20 ng of total DNA per
reaction tube. The standard curve was used to measure the diploid genome copies per sample
2.9. q-PCR for Absolute Telomere Length (aTL)
The SYBR Green KiCqStart ReadyMix (Sigma-Aldrich/Merck) was prepared as per the
manufacturer’s specifications and after preparation, the master mix was mixed. Thereafter 16 µL was
added into each of the 48 wells. In the wells reserved for the standards, 5.2 µL of diluted standard
(10−1 through to 10−6) was added together with 2.8 µL of plasmid DNA (pBR322). 4 µL of the lung
cancer cell line COLO 699 N (ECACC 93052608) positive control and 4 µL of nuclease-free water was
aliquoted into a separate well as the negative template control (NTC). Lastly, 4 µL of the unknown
DNA samples were aliquoted into the remaining reaction wells and the plate was sealed. The cycling
conditions for both the telomere and the 36B4 amplicons were: 10 min at 95 ◦C, followed by 40 cycles
of 95 ◦C for 15 s, 60 ◦C for 1 min, followed by a dissociation curve.
Processing and analyzing of the data was done by exporting the values (Kb/reaction for telomere
and genome copies/reaction for SCG) to csv format. The Kb/reaction value obtained was then used to
determine the total telomere length in Kb per human diploid genome. This was done by dividing the
telomere Kb/per reaction value by the diploid genome copy number to give a total telomeric length in
Kb per human diploid genome.
2.10. Quality Control
After processing, the positive and no signal control (NTC) were checked together with the
amplification in the standards and samples using results from the Telomere STD dilutions. Using these
concentrations, the linear range of the reaction was observed. Those samples which fell outside this
range were removed from further analysis. After amplification was completed the CFX ManagerTM
Software (version 1.6.541.1028) produced a LOG starting value for each reaction that was equivalent to
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Kb/reaction based on the telomere standard curve values. To calculate the inter-assay and intra-assay
coefficient of variations (CV) we performed 20 runs of the control 36B4 SCG in duplicate. The inter-assay
CV was 4.8% and the intra-assay CV was 5.0% for the control sample.
2.11. Statistical Analysis
Data were recorded on an Excel spreadsheet (Microsoft Office Professional 2010) and analyzed
using Statistica (DellTM StatisticaTM 13.2, 2013) and the statistical software R (version 3.3.3, 2017-03-06),
the R Foundation for statistical computing, Vienna, Austria). The Shapiro-Wilk W test was employed
to determine whether continuous variables were normally distributed, based on probability thresholds
of p > 0.1. Due to the departure from a normal distribution for many variables and failure of log
transformation implemented in other studies to approximate normal distribution of TL values in
our sample, general characteristics of the study participants are summarized as median (25th−75th),
and comparisons across glucose tolerance status categories based on Kruskal-Wallis test. Partial
correlations were used to investigate relationships between two continuous variables, while controlling
for the potential effects of age and gender. Due to the lack of significant correlation between most
variables and telomere length, further analyses via multivariable regressions were not pursued.
A p-value of p < 0.05 was used to characterize statistically significant results.
3. Results
3.1. General Characteristics of Participants at Baseline and Three Year Follow Up
Three hundred and fifty-one participants underwent both baseline and three-year follow-up
evaluation. Of these 146 were excluded as they did not consent or did not have sufficient DNA, leaving
205 participants, median age 57 years and 78% being female.
At baseline the glucose tolerance status of participants included 77 (37.6%) normoglycaemia,
43 (21%) pre-diabetes (IFG and/or IGT), 44 (21.4%) new diabetes and 41(20%) with known diabetes.
As expected, the indices of glucose homeostasis, fasting blood glucose (FBG), post 2-hour blood glucose
(PostBG) and glycated hemoglobin (HbA1c) were higher in subjects with prediabetes or diabetes
(all p ≤ 0.0001) while there was no significant difference in Leucocyte Telomere Length at baseline and
three-year follow-up across baseline glucose tolerance status (Table 1).
During the three-year follow-up period 18 participants acquired a status of ‘progression’, including
10 who acquired a diabetes status. There was no significant difference in the LTL between those who
had progressed and those who had remained stable and after three years, the length of the telomeres
was similar to baseline levels (Figure 1 and Table 2).
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Age (Years) 57.0 (48.0; 62.0) 55.0 (46.0; 61.0) 55.0 (45.0; 62.0) 56.0 (47.5; 62.5) 59.0 (54.0; 64.0) 0.0869 59.0 (51.0;66.0) 58.0 (47.0;65.0) 57.0 (48.0;64.0) 60.0 (53.0;65.0) 61.5 (55.0;67.5) 0.0579
BMI 31.7 (27.4;36.5) 29.4 (25.0;33.4) 32.5 (28.7;36.3) 35.0 (30.5;38.1) 31.1 (26.5;37.3) 0.0002 31.3 (27.0;36.6) 29.4 (24.6;35.3) 34.5 (29.2;37.0) 32.9 (30.3;40.3) 31.9 (28.5;36.4) 0.0023
WC (cm) 101.5(93.0;111.0) 96.0 (87.5;106.0) 105.0 (97.0;112.0) 107.7 (101.0;117.5) 101.0 (93.0;114.5) 0.0001 97.3 (88.3;107.0) 92.5 (81.1;105.0) 101.5 (92.3;108.0) 100.0 (99.3;117.3) 98.3 (91.5;109.0) 0.0047
HP (cm) 112.0(104.0;122.7) 109.0 (103.0;116.0) 115.0 (108.0;122.7) 116.5 (108.7;127.0) 111.0 (99.8;125.5) 0.0036 108.8 (98.3;119.3) 105.1 (96.5;113.4) 114.7 (106.1;121.6) 110.7 (104.1;116.0) 110.0 (100.0;120.6) 0.0190
WHR 0.89 (0.85;0.95) 0.88 (0.84;0.92) 0.89 (0.83;0.95) 0.90 (0.86;0.98) 0.92 (0.86;0.96) 0.0371 0.88 (0.83;0.94) 0.88 (0.82;0.93) 0.87 (0.82;0.92) 0.94 (0.88;1.01) 0.91 (0.84;0.96) 0.0098
SBP (mmHg) 123.0(112.0;135.0) 119.0 (111.0;129.0) 121.0 (112.0;132.0) 130.5 (116.0;140.5) 127.0 (114.0;142.0) 0.0259 136.0 (123.0;155.0) 131.0 (120.0;150.0) 142.0 (130.0;157.0) 130.0 (124.0;167.0) 139.0 (126.0;159.0) 0.0264
DBP (mmHg) 76.0 (68.0;83.0) 76.0 (67.0;85.0) 76.0 (68.0;82.0) 77.5 (69.0;86.0) 74.0 (68.0;83.0) 0.7670 82.0 (74.0;90.0) 80.0 (72.0;85.0) 87.0 (77.0;93.0) 84.0 (79.0;97.0) 81.0 (75.0;90.0) 0.0286
FBG (mmol/L) 6.00 (5.00;7.75) 5.10 (4.80;5.60) 6.00 (5.00;6.10) 7.90 (7.10;9.00) 11.05 (6.40;13.05) <0.0001 5.60 (5.00;7.4) 5.00 (4.60;5.4) 5.80 (5.40;6.4) 8.90 (7.50;11.0) 8.55 (6.45;10.9) <0.0001
PostBG
(mmol/L) 7.40 (6.00;10.10) 6.00 (5.40;6.50) 8.60 (8.00;9.20) 13.00 (10.60;17.50) NA <0.0001 6.50 (5.30;8.10) 5.70 (4.90;6.60) 8.40 (7.90;9.00) 15.10 (11.80;19.00) NA <0.0001
Fasting Insulin
(mIU/L) 9.20 (3.80;14.60) 8.30 (3.80;13.70) 10.20 (6.00;14.10) 10.70 (3.60;16.10) 7.80 (2.40; 14.15) 0.5562 12.20 (6.90;17.80) 10.40 (5.60;15.10) 13.20 (6.60;18.80) 17.90 (14.20;27.70) 13.20 (8.75;18.85) 0.0029
FBG/Insulin
ratio 0.71 (0.43;1.62) 0.60 (0.37;1.24) 0.56 (0.40;0.95) 0.74 (0.54;2.22) 1.16 (0.74;3.16) 0.0029 0.56 (0.33;0.88) 0.48 (0.34;0.89) 0.46 (0.30;0.78) 0.50 (0.23;0.75) 0.64 (0.34;0.89) 0.5199
HbA1c (%) 6.10 (5.70;6.80) 5.70 (5.40;6.10) 5.90 (5.80;6.20) 6.75 (6.25;7.70) 7.35 (6.50;8.95) <0.0001 6.20 (5.80;7.00) 5.90 (5.70;6.20) 6.20 (5.95;6.55) 7.40 (6.60;8.80) 7.20 (6.50;8.75) <0.0001
U-CRP (mg/L) 5.50 (1.60;10.40) 4.00 (0.90;7.70) 7.60 (1.80;14.60) 7.10 (2.35;16.90) 4.10 (1.80;8.45) 0.0050 5.30 (2.00;9.20) 5.30 (1.80;11.80) 6.50 (3.90;10.10) 8.20 (4.40;10.40) 3.90 (1.40;7.00) 0.0874
GGT (IU/L) 30.0 (22.0;47.0) 27.0 (18.0;39.0) 31.0 (24.0;47.0) 39.0 (25.0;58.5) 29.5 (20.0;41.5) 0.0056 27.0 (20.0;45.0) 26.0 (19.0;45.0) 27.0 (20.0;46.0) 42.0 (36.0;47.0) 27.0 (20.0;41.5) 0.1010
TC (mmol/L) 5.56 (4.88;6.33) 5.52 (4.92;6.16) 5.53 (4.59;6.30) 5.82 (5.14;6.74) 5.43 (4.74;6.30) 0.3082 5.40 (4.71;6.21) 5.48 (4.76;6.29) 5.46 (5.00;6.08) 5.97 (4.85;6.13) 4.92 (4.53;6.36) 0.4994
TG (mmol/L) 1.37 (1.06;1.92) 1.23 (0.94;1.46) 1.44 (1.10;1.90) 1.58 (1.18;1.96) 1.70 (1.27;2.15) 0.0003 1.36 (0.99;1.75) 1.23 (0.88;1.69) 1.28 (1.01;1.68) 1.53 (1.36;1.94) 1.43 (1.13;1.95) 0.0099
HDL (mmol/L) 1.13 (0.99;1.39) 1.16 (1.00;1.42) 1.15 (1.06;1.39) 1.15 (1.00;1.36) 1.01 (0.86;1.23) 0.0212 1.33 (1.12;1.61) 1.39 (1.20;1.68) 1.21 (1.04;1.46) 1.34 (1.17;1.49) 1.25 (1.09;1.54) 0.0382
LDL (mmol/L) 3.65 (2.92;4.35) 3.63 (3.02;4.16) 3.63 (2.82;4.26) 3.88 (3.16;4.64) 3.38 (2.81;4.47) 0.3836 3.28 (2.68;4.10) 3.28 (2.73;4.03) 3.41 (3.03;4.21) 3.64 (2.75;4.32) 3.00 (2.38;4.06) 0.1795
TC/HDL ratio 4.78 (3.98;5.70) 4.52 (3.70;5.39) 4.51 (3.79;5.12) 4.89 (4.31;6.07) 5.05 (4.32;6.39) 0.0278 3.96 (3.13;4.98) 3.87 (2.97;4.73) 4.26 (3.27;5.52) 3.96 (3.40;5.19) 4.02 (3.19;5.01) 0.2066
S Cotinine
(ng/mL) 9.00 (9.00;261.0) 10.00 (9.00;308.0) 9.00 (9.00;317.0) 9.00 (9.00;184.5) 9.00 (9.00;120.0) 0.0983 9.0 (9.0;289.0) 9.0 (9.0;339.0) 9.0 (9.0;163.0) 212.0 (9.0;334.0) 9.0 (9.0;40.6) 0.0665
Telomere length
(kb) 7.80 (7.50; 8.40) 7.90 (7.50; 8.40) 7.80 (7.50; 8.30) 7.80 (7.50; 8.35) 8.10 (7.50; 8.60) 0.7618 7.90 (7.60; 8.50) 7.90 (7.60; 8.50) 7.80 (7.50; 8.40) 8.40 (8.00; 8.90) 7.90 (7.60; 8.40) 0.2204
Footnote: GGT, γ-Glutamyltransferase; BMI, Body mass index; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; FBG, fasting blood glucose; PostBG, post 2-hour glucose; HP,
Hip circumference; HDL, High density lipoprotein cholesterol; LDL, Low density lipoprotein cholesterol; TC, Total cholesterol; U-CRP, ultra-sensitive C-reactive protein; WC, Waist
circumference; WHR, Waist to hip ratio; S cotinine, serum cotinine. P-values are from the Kruskal-Wallis test.
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Figure 1. There were no significant differences between the telomere length at Baseline and 3‐year 
Follow‐up as categorized by progression and no‐progression; Baseline and Follow‐up for subjects 
who did not progress (N150): Median (range): 7.90 (7.50; 8.40) and 7.90 (7.60; 8.50); for subjects who 
did progress (N18): 8.10 (7.50; 8.40) and 8.05 (7.60; 8.40); p = 0.3328. 
Table 2. Telomere length as measured against the progression of the glucose tolerance status from 
baseline to three‐year follow‐up. 
Glucose Tolerance Status 
Telomere Length  
Baseline  
Telomere Length 
Three-Year Follow-up  
Baseline to Three-Year Follow-Up Median (25,75Q) p-value 
Normoglycemia to Prediabetes, n = 9 7.90 (7.50, 8.30) 7.90 (7.60, 8.20) 0.8385 
Normoglycemia to Diabetes, n = 3 8.40 (7.40, 11.10) 8.40 (8.00, 8.60) 0.5930 
Prediabetes to Diabetes, n = 6 8.05 (7.60, 14.80) 8.15 (7.60, 9.00) 0.7532 
Footnote: P‐values are from the Kruskal‐Wallis test. 
3.2. Correlation between Telomere Length and Glucose Metabolic Parameters 
Because no significant differences were observed across the glucose tolerance statuses and 
telomere length (Table 1), we recategorized participants into prediabetes and diabetes which includes 
both new diabetes and known diabetes. As expected there was a significant negative correlation 
between leucocyte telomere length and age at both baseline and three‐year follow‐up which was 
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Baseline to Three-Year Follow-Up Median (25,75Q) p-Value
Normoglycemia to Prediabetes, n = 9 7.90 (7.50, 8.30) 7.90 (7.60, 8.20) 0.8 85
Normoglycemia to Diabetes, n = 3 8.40 (7.40, 11.10) 8.40 (8. 0, 8.60) 0. 930
Prediabetes to Diabetes, n = 6 8.05 (7.60, 14.80) 8.15 (7.60, 9.00) 0.7532
Footnote: P-values are from the Kruskal-Wallis test.
3.2. Correlation between Telomere Length and Glucose Metabolic Parameters
B cause no significant diff rences were observed across the glucose olerance statuses and
telomere length (Table 1), we recategorized participants into prediabetes and di betes which i cludes
both new diabetes and known diabetes. As expected there was a significant negative correlation
between leucocyte telomere length and age at both baseline and three-year follow-up which was
more pronounced in those subjects who had diabetes (r = −0.18, p = 0.04). Telomere length correlated
negatively with GGT at baseline (r = −0.16, p = 0.027), and at 3-year follow-up there was a positive
correlation with Insulin (p = 0.021) (Table 3).
Cells 2019, 8, 464 8 of 13
Table 3. Partial correlation coefficients controlled for the effects for age and gender, for the association between telomere lengths and anthropometric and biochemical
parameters according to glycemic status after the baseline and the three-year follow-up.
Baseline Three-Year Follow-Up
Variable Overall Prediabetes Diabetes Overall Prediabetes Diabetes
r p r p r p r p r p r p
BMI −0.005 0.944 −0.007 0.937 0.134 0.397 0.044 0.538 0.123 0.198 −0.010 0.976
WC (cm) −0.014 0.846 −0.001 0.993 0.238 0.130 0.022 0.753 0.112 0.243 −0.084 0.805
HP (cm) 0.012 0.868 −0.002 0.981 0.072 0.650 0.020 0.778 0.044 0.650 0.362 0.304
WHR −0.048 0.499 −0.003 0.977 0.198 0.209 −0.003 0.968 0.095 0.330 −0.487 0.154
SBP (mmHg) 0.003 0.966 0.037 0.677 0.348 0.024 −0.065 0.358 0.020 0.836 −0.389 0.237
DBP (mmHg) −0.021 0.763 −0.012 0.897 0.228 0.146 0.038 0.593 0.124 0.194 −0.154 0.650
FBG (mmol/L) 0.020 0.780 −0.007 0.937 −0.013 0.935 0.048 0.496 0.066 0.491 0.187 0.582
PostBG (mmol/L) −0.023 0.772 −0.073 0.506 −0.151 0.339 0.146 0.091 0.216 0.149 −0.044 0.897
Fasting Insulin (mIU/L) −0.017 0.811 0.000 0.997 0.079 0.625 0.022 0.755 0.146 0.125 0.681 0.021
FBG/Insulin ratio −0.044 0.536 −0.040 0.662 −0.037 0.818 −0.010 0.888 −0.036 0.707 −0.123 0.719
HbA1c (%) 0.046 0.520 0.024 0.794 −0.022 0.888 0.050 0.478 0.083 0.385 0.150 0.659
U-CRP (mg/L) 0.073 0.300 0.116 0.198 −0.133 0.400 0.015 0.831 −0.030 0.756 −0.199 0.557
GGT (IU/L) −0.156 0.027 −0.173 0.054 −0.176 0.264 0.127 0.072 0.092 0.335 0.096 0.778
TC (mmol/L) 0.024 0.733 0.035 0.699 0.168 0.289 −0.012 0.867 0.008 0.934 −0.224 0.508
TG (mmol/L) −0.011 0.877 −0.058 0.520 −0.165 0.295 −0.002 0.978 0.007 0.938 −0.163 0.632
HDL (mmol/L) 0.109 0.121 0.073 0.416 0.193 0.220 0.041 0.558 0.017 0.856 0.171 0.615
LDL (mmol/L) −0.003 0.969 0.043 0.637 0.224 0.153 −0.028 0.693 0.005 0.961 −0.223 0.510
TC/HDL ratio −0.039 0.579 −0.001 0.989 −0.034 0.829 −0.040 0.573 −0.027 0.781 −0.337 0.310
S Cotinine (ng/mL) 0.065 0.357 0.077 0.396 −0.173 0.274 −0.050 0.482 −0.137 0.151 −0.512 0.107
S. Creatinine (umol/L) 0.058 0.408 0.100 0.269 0.138 0.382 −0.042 0.548 −0.041 0.665 0.317 0.342
Footnote: GGT, γ-Glutamyltransferase; BMI, Body mass index; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; FBG, fasting blood glucose; PostBG, post 2-hour glucose; HP,
Hip circumference; HDL, High density lipoprotein cholesterol; LDL, Low density lipoprotein cholesterol; TC, Total cholesterol; U-CRP, ultra-sensitive C-reactive protein; WC, Waist
circumference; WHR, Waist to hip ratio; S cotinine, serum cotinine; S.Creatinine, serum creatinine. P-values are from Partial correlations.
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4. Discussion
The principal findings of this longitudinal study of mixed ancestry South Africans were that
leucocyte telomere length (LTL) was not significantly different between the four glucose tolerance
groups. Although high rates of deterioration of glucose status occurred over time there was no
significant difference in the telomere length after three years, including in subjects who showed
deterioration of their glucose tolerance status. There was a significant negative correlation between
LTL and GGT at baseline which remained after adjustment for age and gender.
Telomeres, the tandem repeats of TTAGGG DNA sequence situated at the ends of linear
chromosomes shorten after each cell division [20]. As a result, the telomere length is an indicator of
biological aging [21], as well as age-related disorders, such as type 2 diabetes [6,13,22]. In our study,
we included participants with normal glucose tolerance, prediabetes, undiagnosed diabetes and those
with diabetes on treatment. Telomere length was not significantly different across all these glucose
tolerance status groups.
Although a number of studies have shown an association between telomere length and
diabetes [23–31] in some, this association was weak [28], cell type dependent [24] or associated
with heart disease [30,31]. Sampson et al. measured the telomere length of peripheral blood monocytes
and T-cells in Type 2 diabetes and normal controls. This study was performed using fluorescent
in situ hybridization and significantly lower mean monocyte telomere length was reported in the
diabetes group [24]. On the other hand, similar to our findings, some studies have failed to show an
association between telomere length and diabetes. In one of these, Type 2 diabetes patients, without
any complications demonstrated that, leucocyte telomere length was not significantly different to
normoglycemic control subjects [30]. Similarly, in patients with type 2 diabetes, a median of 1 year
from diagnosis, no difference in peripheral leucocyte TL was demonstrated when compared to
age-matched non-diabetes control subjects [32]. Reasons for the variation in reported results could be
attributed to a number of factors which include differing methodologies, patient populations, treatment
and complications.
Terminal restriction fragmentation has been described as the gold standard to measure telomere
length, but due to the need for large quantities of DNA, a number of PCR based methods have been
developed. These include q-PCR [33] and a modification of this technique, which incorporated the use
of a standard curve to measure absolute telomere length [19].
Other researchers have utilized Quantitative Fluorescence in situ Hybridization (Q-FISH) and
Flow –FISH, which has the advantage of sorting and isolating different haemopoietic cell populations
using a flow cytometer before measuring telomere length using a peptide nucleic probe (PNA) [34].
Each of the above techniques has advantages and disadvantages which could lead to variations in
the reported results. Causes of variation could include the quantity and quality of extracted DNA,
variation in pipetting techniques, the cell population being analyzed and the expertise of the person
performing the test [35]. In this study, the q-PCR method described by O’Callaghan et al. [19] was used
and in order to overcome some of the challenges, the quality of the DNA was assessed using a nanodrop
and only those with an OD (optical density) ratio A260/A280 > 1.8 were used. Furthermore, strict quality
control measures were adhered to and all samples were analyzed in triplicate. However, as the
measurement of telomere length is not fully standardized, comparing research remains challenging
and controversial.
It is well recognized that telomere length shortens with age and occurs at a constant rate [21].
We however, did not find a significant difference in the telomere length after three years, including in
subjects who progressed to a worse glucose tolerance status. It could be that a three-year timeframe is
not a sufficient period of time or that the sample was too small to assess change in telomere length.
In a study conducted on 2328 American Indian participants, LTL was assessed as a predictor of
developing diabetes. Two hundred and ninety two developed the disease within a five year follow up
period and it was determined that shorter LTL significantly and independently predicted an increased
risk of developing diabetes [36]. In a similar study of 606 participants, 44 developed T2DM over
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a 15-year follow-up period and it was again concluded that there was a significant association between
shorter leucocyte telomeres and risk of T2DM development [13]. In contrast however, an earlier study
evaluating incident diabetes participants over a six-year follow-up timeframe could only demonstrate
a weak association between LTL and diabetes risk and no statistically significant association was
found [28].Therefore, while there is clear evidence for the effect of diabetes and its metabolic effects,
such as low-grade inflammation and oxidative stress on telomere integrity, these contradictory reports
are difficult to interpret and it appears that further large prospective studies over longer time frames
are required.
Hyperglycemia affects biochemical pathways leading to glucose oxidation, advanced glycation
end product (AGE) formation and activation of polyol pathways which are all associated with the
production of reactive oxygen species (ROS) and increased oxidative stress [37–39]. Studies have
reported elevated levels of oxidative stress markers, such as glucose-6-phosphate dehydrogenase
(G6PDH), malondialdehyde (MDA), glutathione (GSH), glutathione reductase (GR), glutathione
peroxidase (GPx) and superoxide dismutase (SOD) [40] in Type 2 diabetes, while a negative correlation
between oxidative stress and LTL has been demonstrated [26,41]. Further investigations in Type 1
and Type 2 diabetes examined oxidative stress by quantifying 8-hydroxy-desoxyguanosine (8-OHdG)
and demonstrated a significant association with shortened telomeres in both types of diabetes [29].
A limitation of this current study was that we were unable to confirm this link as markers of oxidative
stress were not included.
Although telomeres are progressively lost with each cell division, a minimal extension does occur.
This extension is attributed to the activity of telomerase, a reverse transcriptase enzyme [41]. Previous
research has demonstrated a positive relationship between exercise and telomere length maintenance
with subsequent lengthening. After a four-and-a-half-year follow-up period, an increase in LTL was
observed in two-thirds of obese individuals with impaired glucose metabolism after significant lifestyle
interventions were implemented. It was concluded from this that LTL can increase with time if positive
healthy lifestyle interventions are initiated [41,42].
In our study, a significant negative correlation, which was more pronounced in subjects with
diabetes, was observed between LTL and Gamma-glutamyl transferase (GGT). Gamma-glutamyl
transferase is a sensitive but nonspecific index of liver dysfunction and could indicate excessive alcohol
intake [43]. Previous studies have associated alcohol abuse with shortened telomeres, and premature
cellular aging [44] which could provide an explanation for our findings. The link between high levels
of GGT and the risk of developing Type 2 diabetes, however, remains unclear [45] but in a study of
men aged 35-55 years, adjusted for confounders, such as BMI and alcohol drinking, it was found
that the risk for developing diabetes increased with elevated GGT levels [46]. This study has been
supported by previous work conducted among 1198 individuals from the Bellville-South region in Cape
Town, in which GGT levels were independently associated with insulin sensitivity and obesity [47].
These studies suggest that chronic high levels of GGT may be an indicator of insulin resistance and this
link may be important in the context of our results.
In summary, this longitudinal study has demonstrated no significant difference in the LTL between
the baseline and the three year follow up. It is, however, important to highlight the limitations of this
study which include the short follow up period, the small sample size and the mixed population which
could have contributed to the increased variability in the telomere length. Furthermore, it is well
documented that males have shorter telomeres than females [48] and as the majority of the participants
were female (75%) this may have further influenced the results. A further limitation was that the
inter-assay CV was below the recommended 7% even though the intra-assay CV was slightly higher.
However, despite these limitations this study has provided important information and future work
aims to include larger numbers of participants and over a longer period.
Telomere length is influenced by a number of factors, including oxidative stress, high levels of
inflammation and cell type, all of which were not fully explored in this study. Future investigations
aim to examine the length of telomeres in different immune cell types and include oxidative stress
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markers, such as 8-OHdG. Telomere length has been well established as a marker of aging and
age-related disorders and therefore additional knowledge of what influences telomere shortening in
T2DM and other metabolic disorders could contribute to interventions that assist in the prevention of
complications, such as cardiovascular disease.
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